Overview

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Niacinamide
Sorafenib